Adjuvant endocrine therapy in pre- and perimenopausal women with breast cancer: practice guidelines
(2016) Belgian Journal of Medical Oncology — Vol. 10, n° 3, p. 92-96 (2016)
Files
PracticeGuidelines.pdf
Open Access - Adobe PDF
- 108.61 KB
Details
- Authors
- Abstract
- Oestrogen receptor positive early invasive breast cancer is a common disease in pre- and perimenopausal women. Adjuvant endocrine therapy is an essential part of its treatment. Until recently, premenopausal patients were uniformly treated with tamoxifen during fi ve years. Given the recent publication of large clinical trials showing a benefi t for other treatment regimens, the BSMO Breast Cancer Task Force met on the 6th of March, 2015, to propose common guidelines for adjuvant endocrine therapy for premenopausal patients. The members agreed that low-risk patients should be treated with fi ve to ten years of tamoxifen, while the highest-risk patients should be treated with exemestane or tamoxifen plus ovarian function suppression. Special attention should be given to patients less than 35 years at diagnosis: in this subgroup, exemestane plus ovarian function suppression is preferred to tamoxifen plus ovarian function suppression.
- Affiliations
Citations
Duhoux, F., Neven, P., Awada, A., Berlière, M., Wildiers, H., & Denys, H. (2016). Adjuvant endocrine therapy in pre- and perimenopausal women with breast cancer: practice guidelines. Belgian Journal of Medical Oncology, 10(3), 92-96. https://hdl.handle.net/2078.5/90093 (Original work published 2016)